Please take a moment to review the latest ASCO News
- Executive Orders and Cancer Care
- Medicare Advantage, Part D, PACE Proposal Aims for Transparency in Prior Authorization and AI Practices
- Four Cancer Drugs Included in Next Round of Part D Drug Price Negotiation
- Recommendations to Reduce Out-of-Pocket Costs for People with Cancer Detailed in New ASCO Position Statement
- FDA Approves Treosulfan with Fludarabine as a Preparative Regimen for Allohsct in Adult and Pediatric Patients with AML or MDS
- Oncology Society Applauds Efforts to Prevent Tobacco Uptake, Addiction by Lowering Nicotine Levels
- FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic, HR-positive, HER2-negative Breast Cancer
- FDA Approves Sotorasib with Panitumumab For KRAS G12C-Mutated Colorectal Cancer
- FDA Approves Acalabrutinib with Bendamustine and Rituximab for Previously Untreated Mantle Cell Lymphoma
- Cybersecurity Proposal Would Establish Minimum Standards for Most Health Plans, Providers, Businesses
- Advocating for Cancer Care, Research Priorities in New Congress; Participate in ASCO’s Efforts
- ASCO Applauds New Draft Guidance on Including Tissue Biopsies in Clinical Trials
- States Convene for 2025 Legislative Session
- Transform your Advocacy Impact in Just 5 Steps
- Oncology Society Urges Americans to Heed Surgeon General Advisory on Alcohol and Cancer